Simplify Asset Management Inc. Purchases Shares of 70,430 4D Molecular Therapeutics, Inc. $FDMT

Simplify Asset Management Inc. acquired a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) in the 1st quarter, HoldingsChannel.com reports. The fund acquired 70,430 shares of the company’s stock, valued at approximately $656,000.

Other large investors have also recently added to or reduced their stakes in the company. Martingale Asset Management L P grew its stake in shares of 4D Molecular Therapeutics by 12.4% in the fourth quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock worth $88,000 after purchasing an additional 1,303 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in 4D Molecular Therapeutics by 3.7% in the third quarter. Dimensional Fund Advisors LP now owns 58,006 shares of the company’s stock worth $504,000 after purchasing an additional 2,069 shares during the period. Russell Investments Group Ltd. grew its position in 4D Molecular Therapeutics by 11.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock valued at $81,000 after buying an additional 2,284 shares in the last quarter. Prelude Capital Management LLC raised its position in shares of 4D Molecular Therapeutics by 11.1% during the 3rd quarter. Prelude Capital Management LLC now owns 23,000 shares of the company’s stock worth $200,000 after buying an additional 2,300 shares in the last quarter. Finally, Impact Partnership Wealth LLC lifted its stake in shares of 4D Molecular Therapeutics by 36.5% in the 4th quarter. Impact Partnership Wealth LLC now owns 15,123 shares of the company’s stock worth $113,000 after acquiring an additional 4,045 shares during the period. 99.27% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

FDMT has been the topic of a number of research analyst reports. Chardan Capital reiterated a “buy” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. Royal Bank Of Canada upped their price objective on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a report on Thursday, March 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Monday, April 20th. The Goldman Sachs Group set a $33.00 price target on shares of 4D Molecular Therapeutics in a research report on Friday, May 8th. Finally, Jefferies Financial Group restated a “buy” rating and set a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $29.88.

4D Molecular Therapeutics Stock Performance

Shares of FDMT opened at $13.00 on Friday. 4D Molecular Therapeutics, Inc. has a 1-year low of $3.86 and a 1-year high of $14.00. The stock has a market capitalization of $679.64 million, a P/E ratio of -5.06 and a beta of 2.70. The business’s 50-day moving average price is $9.87 and its 200 day moving average price is $9.23.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The firm had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $2.59 million. On average, research analysts predict that 4D Molecular Therapeutics, Inc. will post -4.14 earnings per share for the current year.

Insiders Place Their Bets

In other 4D Molecular Therapeutics news, insider David Kirn sold 114,746 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $10.47, for a total value of $1,201,390.62. Following the transaction, the insider owned 942,485 shares in the company, valued at approximately $9,867,817.95. This represents a 10.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Scott Bizily sold 9,810 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the sale, the insider owned 8,617 shares of the company’s stock, valued at approximately $103,404. The trade was a 53.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 126,478 shares of company stock valued at $1,338,369 in the last 90 days. Corporate insiders own 7.90% of the company’s stock.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.